Metabolomic, a recent tool exploited to explore the complex interactions of metabolites in livelihood systems, discloses the metabolic response to pathophysiologic stimuli or genetic alterations ([@B1]). In recent years, metabolomic has been fruitfully applied in clinical settings, including diabetes ([@B2],[@B3]). In type 2 diabetes, alteration of lipid and, in particular, of fatty acid metabolism is a common feature ([@B4]). A linear correlation among blood glucose levels, hepatic glucose production, and nonesterified fatty acid (NEFA) plasma levels has been reported in diabetes ([@B4]). Indeed, total NEFA is considered an important index for type 2 diabetes diagnosis ([@B5]). Recently, metabolic profiling of plasma NEFAs in type 2 diabetic patients has discovered different biomarkers, and palmitic acid (PA), a 16-carbon saturated fatty acid, accounting for ∼30% of total plasma NEFAs ([@B6]), has been considered a reliable one ([@B3],[@B5]).

NEFAs act both as ligands for cell-surface receptors (e.g., G-protein--coupled receptors) and for transcription factor receptors as peroxisome proliferator--activated receptors (PPARs). PPARs are crucial transcriptional regulators of genes involved in glycemic control, lipid metabolism, and inflammation ([@B7]). Three different PPAR isoforms characterized by unique functions and denoted as α, β/δ, and γ have been described ([@B8]). PPARγ, a key mediator in adipogenesis ([@B9]), lipid metabolism ([@B10]), and glucose homeostasis ([@B11]), also controls target genes involved in vascular biology and diabetes-associated vascular complications ([@B8],[@B12]). Cardiovascular risk factors, such as diabetes, reduce endothelial progenitor cell (EPC) bioavailability by impairing their mobilization, proliferation, and integration into injured vascular sites, crucial events for vessel repair ([@B13]). In recent years, evidence for PPARγ-mediated vascular protection in diabetic patients has been provided ([@B14]). A great deal of interest on PPARγ agonists was generated by the finding that they can avoid progression of vascular disease by improving EPC functions ([@B15]). However, whether such effect depends on a direct action on EPCs and/or on their effect on glucose metabolism is still debated ([@B16]). Moreover, as in type 2 diabetes NEFA concentrations ([@B17]) and changes in EPC number and functional capability are closely associated with cardiovascular risk factor profile ([@B13],[@B18]), whether NEFA concentrations, by triggering PPARγ activity, impact on EPC bioavailability is still an unsolved issue ([@B19],[@B20]).

PPARγ mainly forms heterodimers with the nuclear retinoid X receptor-α ([@B8]) and binds to PPAR response elements in the regulatory regions of target genes ([@B21]). Moreover, PPARγ also forms a transcriptional complex with the signal transduction and activator of transcription 5 (STAT5) to control EPC cell-cycle progression ([@B22]). However, agonist-dependent, unlike agonist-independent, PPARγ expression led to impaired hematopoietic progenitor functions ([@B23]), and inhibition of EPC proliferation ([@B19],[@B20]). Thus, physiological PPARγ agonists, as PA, by impairing EPC bioavailability, can actually contribute to vascular damage in a diabetic setting.

In the current study, we investigated whether and how mechanistically high plasma levels of PA could affect EPC bioavailability and possibly contribute to diabetes-associated vascular damage.

RESEARCH DESIGN AND METHODS {#s1}
===========================

Reagents. {#s2}
---------

A detailed list of the reagents and antibodies used in this study is reported in [Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0646/-/DC1).

Diabetic subjects and healthy donors. {#s3}
-------------------------------------

Whole blood was recovered from 14 individuals with type 2 diabetes selected at the diagnosis (two independent fasting glucose determinations) and from 14 sex- and age-matched healthy donors. Four additional longstanding diabetic patients were enrolled. Data relative to patients and control subjects are reported in [Table 1](#T1){ref-type="table"}. Ethical approval was obtained from Servizio Immunoematologia e Medicina Trasfusionale, Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant Anna (Torino, Italy). Informed consent was obtained in accordance with the Declaration of Helsinki.

###### 

Data referred to diabetic patients and healthy subjects

![](1245tbl1)

Isolation and culture of EPCs and endothelial cells. {#s4}
----------------------------------------------------

Isolation and characterization of EPCs and mature endothelial cells (ECs) were performed as described ([@B24],[@B25]). To isolate EPCs, peripheral blood mononuclear cells were obtained by Ficoll Histopaque 1077 and plated onto collagen-1--coated dishes. Fluorescence-activated cell sorting (FACS) analysis was used to characterize EPC surface markers. At day 14, cells were depleted with serum-free medium for 12 h and then challenged with EGM-2 medium containing PA, 100 μmol/L physiologic PA (*n*-PA) or 300 μmol/L diabetic PA (*d*-PA), and ethanol-BSA (not exceeding 0.15% and 0.003% final concentration, respectively) as control. In selected experiments, oleic acid (OA) and stearic acid (SA) at the same molar concentrations were used.

Isolation of bone marrow--derived hemopoietic cells and CFU assay. {#s5}
------------------------------------------------------------------

Bone marrow (BM)--derived hemopoietic cells (an additional model of immature cells) were obtained from murine bone marrow flushed from the femurs and tibiae of 10--12-week-old FVB mice and isolated by Ficoll Histopaque 1083. CD117/c-kit^+^ cells were sorted with the CD117 magnetic MicroBeads Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) following the manufacturer's protocol. Sorted cells were seeded (1 × 10^5^ cells/mL) (BM-CD117^+^) in methylcellulose containing complete medium and cultured for 15 days. Ethanol-BSA was used as control. At the end of the experiments, individual colonies (\>100 cells) were counted with a scoring grid using an inverted microscope.

Preparation of fatty acid--albumin complexes. {#s6}
---------------------------------------------

Saturated PA and SA or monounsaturated OA were used. Lipid-containing media were prepared by conjugating free fatty acids with BSA using a modified method described by Svedberg et al. ([@B26]). Preliminary experiments were performed with delipidated sera as described by Cham and Knowles ([@B27]). Because no significant differences were observed in pilot experiments, nondelipidated sera were used throughout the study.

Migration assay. {#s7}
----------------

EPC migration was performed in Boyden's chambers as previously described ([@B28]).

Reactive oxygen species generation and senescence. {#s8}
--------------------------------------------------

Reactive oxygen species generation and senescence were evaluated as previously described ([@B25],[@B28]).

Cell-cycle progression and proliferation assay. {#s9}
-----------------------------------------------

Cell-cycle progression was evaluated by FACS analysis ([@B22]). The percentage of cells in each cell-cycle phase was determined by ModFit LT software (Verity Software House, Inc., Topsham, ME). Cell proliferation was also assayed by direct cell count by three different operators and by evaluating the percentage of proliferating cell nuclear antigen (PCNA)-positive cells by FACS analysis.

Western blotting and coimmunoprecipitation. {#s10}
-------------------------------------------

Western blotting (WB) analysis and coimmunoprecipitation (co-IP) experiments on EPCs treated as indicated were performed as previously described ([@B22],[@B28],[@B29]). Images were acquired with a Bio-Rad GS 250 molecular imager (Bio-Rad, Hercules, CA), and densitometric analysis was performed using the software ImageJ 1.45 m (National Institutes of Health).

RNA isolation and quantitative real-time PCR. {#s11}
---------------------------------------------

Quantitative real-time polymerase chain reactions (q-RT-PCRs) were performed as described ([@B28],[@B29]). Primers are reported in [Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0646/-/DC1).

Bioinformatic analysis. {#s12}
-----------------------

Bioinformatic analysis of putative response elements on *Homo sapiens* STAT5 gene (AC_099811), *Homo sapiens* cyclin D1 promoter (Z29078.1), *Homo sapiens* p21^Waf^ (NG_009364.1), *Mus musculus* cyclinD1 (sequence NC_000073) gene, and *Mus musculus* p21^Waf^ (sequence NC_000083) were performed using the following software: NHRScan (<http://asp.ii.uib.no:8090/cgi-bin/NHR-scan/nhr_scan.cgi>) for the PPAR putative response element (PPRE) sequence and Motif (<http://www.genome.jp/tools/motif/>) for STAT5 response elements. The results were then verified with Transcription Element Search Software (<http://agave.humgen.upenn.edu/utess/tess>).

Chromatin immunoprecipitation. {#s13}
------------------------------

Chromatin immunoprecipitation (ChIP) assay was performed using a Magna ChIP kit (Millipore, Temecula, CA) ([@B22]). Primers are reported in [Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0646/-/DC1).

Electrophoretic mobility shift assay. {#s14}
-------------------------------------

Nuclear extracts were prepared as previously described ([@B22],[@B30]). Oligonucleotides used are reported in [Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0646/-/DC1).

Endogenous depletion of PPARγ by small interfering RNA. {#s15}
-------------------------------------------------------

EPCs were transiently transfected with specific PPARγ small interfering RNA (siRNA) and with duplex siRNAs as scramble controls, purchased from Qiagen (Valencia, CA) ([@B22]).

Constitutively activated STAT5 form transfection. {#s16}
-------------------------------------------------

Fifteen-day--cultured EPCs were transiently transfected with a plasmid constitutively activated STAT5 form (STAT1\*6) or the empty vector pCNeo as described ([@B22],[@B31]).

Luciferase gene reporter and site-directed mutagenesis. {#s17}
-------------------------------------------------------

The luciferase reporter assay was performed using three different constructs generated by subcloning into restriction sites of the luciferase reporter vector pGL3 Basic Vector (Promega, Madison, WI) two different sequences of the human STAT5A promoter region, amplified using TaKaRa LA Taq (Takara Bio-Europe SAS, Saint-German-en-Laye, France) from human genomic DNA. All fragments were inserted to obtain three different plasmids: pGL3-A3, pGL3-Inter2, and pGL3-Inter2-A3. A site-direct mutagenesis on the latter plasmid was performed as described by Weiner et al. ([@B32]). Primers are reported in [Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0646/-/DC1).

Vasculogenetic assay. {#s18}
---------------------

EPC vasculogenic capability was evaluated in vitro and in vivo as previously described ([@B28],[@B29],[@B33]).

Statistical analysis. {#s19}
---------------------

Comparison and significance of differences between two groups was performed with the *t* test. Comparison among three or more groups was performed with one-way ANOVA, and significance of differences was evaluated with the Newman-Keuls multicomparison posttest. The *P* values \<0.05 were considered significant and indicated with different symbols as detailed in the figure legends. All statistical analyses were carried out with GraphPad Prism version 5.04 software (GraphPad Software, Inc.).

RESULTS {#s20}
=======

Diabetic concentrations of PA impair EPC functions. {#s21}
---------------------------------------------------

In diabetic patients, plasmatic PA concentration rises up to three- to fivefold when compared with matched healthy subjects ([@B34]) and seems to impair EPC functions ([@B19],[@B20]). We attempted to investigate the molecular mechanisms accounting for this effect. EPCs were characterized and PA dose-response experiments performed ([Supplementary Figs. 1 and 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0646/-/DC1)) by evaluating the expression of two cell-cycle regulatory proteins: cyclin D1 and p21^waf^ ([@B25]). We demonstrated that only for doses greater than or equal to PA 300 μmol/L, diabetic concentrations (*d*-PA), cyclin D1 and p21^waf^ content changed. Parallel experiments performed with physiological and diabetic SA concentrations demonstrated that such saturated fatty acid had no significant effect on cell-cycle regulatory proteins and EPC proliferation and migration ([Supplementary Fig. 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0646/-/DC1)). To validate the biological relevance of these results, EPCs were cultured with physiological (100 μmol/L *n*-PA) or *d*-PA concentrations. As shown in [Fig. 1*A*](#F1){ref-type="fig"}, only *d*-PA treatment induced a decrease in the number of cells. Cell-cycle analysis ([Fig. 1*B*](#F1){ref-type="fig"}) demonstrated that this effect is not associated with cell death ([Supplementary Fig. 4*A--C*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0646/-/DC1)). Cytofluorimetric analysis of PCNA ([Fig. 1*C*](#F1){ref-type="fig"}) and expression of cyclin D1 and p21^Waf^ are consistent ([Fig. 1*D* and *E*](#F1){ref-type="fig"}). *d*-PA did not induce ROS generation and EPC senescence ([Supplementary Fig. 4*D* and *E*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0646/-/DC1)). Moreover, impaired EPC migratory capability was detected upon *d*-PA treatment ([Fig. 1*F*](#F1){ref-type="fig"}). Conversely, *d*-PA did not affect mature EC proliferation and migration ([Supplementary Fig. 5](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0646/-/DC1)).

![*d*-PA, unlike *n*-PA, impairs EPC functions. *A*: EPC proliferation in response to the indicated stimuli (data are expressed as mean + SD; *n* = 6; \**P* \< 0.05, *d*-PA 48 h vs. C \[control\] 48 h; \*\**P* \< 0.01, *d*-PA 72 h vs. C 72 h). *B*: FACS analysis indicating the percentage of EPCs at different cell-cycle phases (referred at 48 h) (data are expressed as mean, *n* = 6). *C*: FACS analysis of PCNA-positive EPCs treated as indicated (referred at 48 h). The reported graph is representative of six independent experiments. *D*: q-RT-PCR analysis of cyclin D1 and p21^Waf^ mRNA expression in 48 h--treated EPCs as indicated. Data normalized to the corresponding glyceraldehyde-3-phosphate dehydrogenase mRNA and expressed as mean + SD are reported as fold induction relative to control values arbitrary set as 100 (*n* = 9; \*\**P* \< 0.01, cyclin D1 *d*-PA vs. C and *n*-PA; ††*P* \< 0.01, p21^Waf^ *d*-PA vs. C and *n*-PA). *E*: Representative WB and densitometric analysis of cyclin D1 and p21^Waf^ protein content in 48 h--treated EPCs. Densitometric data, normalized to the corresponding β-actin value and expressed as mean + SD, are reported as fold induction relative to control values arbitrarily set as 100 (*n* = 9; \*\**P* \< 0.01, cyclin D1 *d*-PA vs. C and *n*-PA; †††*P* \< 0.001, p21^Waf^ *d*-PA vs. C and *n*-PA). IL-3-- and AGE-stimulated ECs were used as positive controls for cyclin D1 or p21^Waf^, respectively. *F*: EPC migration in response to stromal cell--derived factor 1α (SDF-1α) (20 ng/mL). Data are expressed as mean + SD (*n* = 6; \*\**P* \< 0.01, *d*-PA vs. C and *n*-PA).](1245fig1){#F1}

Beneficial effects are exerted by monounsaturated fatty acid, as OA ([@B35],[@B36]). The effects of OA on EPC proliferation and migration were evaluated at physiological (100 μmol/L *n*-OA) and diabetic (300 μmol/L *d*-OA) concentrations. Indeed, *d*-OA concentration had no significant effects on EPC proliferation and migration ([Fig. 2*A*, *B*, and *D*](#F2){ref-type="fig"}). Data were further sustained by cyclin D1 and p21^Waf^ expression ([Fig. 2*B*](#F2){ref-type="fig"}). However, when added to *d*-PA, only *n*-OA rescued *d*-PA--mediated EPC cell-cycle arrest and migration ([Fig. 2*C*--*E*](#F2){ref-type="fig"}).

![EPC proliferation and migration upon OA treatment. *A*: Proliferation of EPCs treated as indicated; data are expressed as mean + SD (*n* = 6). *B*: Representative WB and densitometric analysis of cyclin D1 and p21^Waf^ protein content in 48 h--treated EPCs as indicated; densitometric data normalized to the corresponding β-actin value and expressed as mean + SD are reported as fold induction relative to control values arbitrarily set as 100. *C*: EPC number after 48-h treatment (data are expressed as mean + SD, *n* = 9; \**P* \< 0.05, *d*-PA vs. no stimulus and *d*-PA + *n*-OA; \*\**P* \< 0.01, *d*-PA + *d*-OA vs. no stimulus and *d*-PA + *n*-OA). *D*: EPC migration in response to SDF-1α. EPCs were treated for 48 h as indicated. Data are expressed as mean + SD (*n* = 6; \**P* \< 0.05, *n*-OA + *d*-PA vs. no stimulus, *n*-OA, and *d*-OA; \*\**P* \< 0.01, *d*-PA and *d*-OA + *d*-PA vs. no stimulus, *n*-OA, and *d*-OA). *E*: Representative WB and densitometric analysis of cyclin D1 and p21^Waf^ protein content in 48 h--treated EPCs as indicated; densitometric data, normalized to the corresponding β-actin values and expressed as mean + SD, are reported as fold induction relative to control values arbitrarily set as 100 (*n* = 9; \*\**P* \< 0.01, cyclin D1 *d*-PA and *d*-PA + *d*-OA vs. no stimulus and *d*-PA + *n*-OA; ††*P* \< 0.01, p21^Waf^ *d*-PA and *d*-PA + *d*-OA vs. no stimulus and *d*-PA + *n*-OA). IL-3-- and AGE-stimulated ECs were used as positive controls for cyclin D1 or p21^Waf^, respectively (C+, *B* and *E*).](1245fig2){#F2}

*d*-PA induces PPARγ expression and downregulation of STAT5A transcription. {#s22}
---------------------------------------------------------------------------

Although both IL-3 and synthetic or natural PPARγ agonists activate PPARγ expression, only IL-3 induced EPC expansion via the formation of a STAT5/PPARγ transcriptional complex ([@B22],[@B29]). PA is natural PPARγ agonist ([@B37],[@B38]), thus the effect of *d*-PA and *n*-PA on PPARγ and STAT5 expression was first evaluated. Accordingly with previous data ([@B22]), *d*-PA only induced PPARγ expression and decreased STAT5A expression ([Fig. 3*A--C*](#F3){ref-type="fig"}). No changes in STAT5B expression were detected, suggesting that PPARγ directly controls STAT5A transcription ([Fig. 3*D*](#F3){ref-type="fig"}). To validate this possibility, the STAT5 gene promoter was analyzed to find PPREs. Three different regulatory regions have been identified in the human STAT5 gene promoter ([@B39]). Regions I and II are putative STAT5A and STAT5B promoters, respectively, whereas region III acts as a negative regulatory element for both genes. Regions I--III contain different functional sequences denoted A1, A2, and A3 (region I) and Inter1 and Inter2 (region III) ([@B39]). Consistent with the presence (NHRScan bioinformatic software) of two different putative PPREs in A3 and Inter 2 regions, ChIP analysis demonstrated that PPARγ binds to A3 and the Inter2 regulatory regions of STAT5 promoter ([Fig. 3*E*](#F3){ref-type="fig"}). To further validate this result, the two STAT5 genomic fragments, A3 and Inter 2, were cloned as single fragment or juxtaposed to reproduce the whole regulatory region of the STAT5A gene in the pGL3 luciferase reporter vector and denoted as: pGL-A3, pGL-Inter2, and pGL-Inter2:A3 ([Fig. 3*G*](#F3){ref-type="fig"}). Consistent with ChIP analysis, luciferase assay showed that PPARγ even at low concentrations binds to A3 and positively regulates STAT5 transcription. Conversely, PPARγ binds to Inter2 to negatively regulate STAT5 transcription only in *d*-PA--treated EPCs, expressing pGL-Inter2-- or pGL-Inter2:A3--containing regions ([Fig. 3*G*](#F3){ref-type="fig"}). By site-directed mutagenesis, we confirmed that the Inter2 region is crucial for *d*-PA--mediated inhibition of STAT5A transcription ([Fig. 3*G*](#F3){ref-type="fig"}). Similar results were obtained when electrophoretic mobility shift assay analysis was performed ([Fig. 3*F*](#F3){ref-type="fig"}). By silencing PPARγ, we also demonstrated its biological relevance in mediating inhibition of STAT5A and p21^Waf^ expression, cell-cycle progression, and migration in response to *d*-PA ([Supplementary Fig. 6](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0646/-/DC1)).

![*d*-PA induces PPARγ expression that leads to STAT5A transcription inhibition. *A*: Representative WB and densitometric analysis of PPARγ, phosphorylated STAT5 (pSTAT5), and STAT5 protein content in EPCs treated for 24 and 48 h as indicated; densitometric data, normalized to the corresponding β-actin values and expressed as mean + SD, are reported as fold induction relative to control values arbitrarily set as 100 (*n* = 9; \*\**P* \< 0.01, PPARγ *d*-PA 24 h vs. C (control) 24 h and *n*-PA 24 h and also PPARγ *d*-PA 48 h vs. C 48 h and *n*-PA 48 h; †*P* \< 0.05, pSTAT5 *d*-PA 24 h vs. C 24 h and *n*-PA 24 h; ‡*P* \< 0.05, STAT5: *d*-PA 24 h vs. C 24 h and *n*-PA 24 h; ††*P* \< 0.001, pSTAT5 *d*-PA 48 h vs. C 48 h and *n*-PA 48 h; ‡‡*P* \< 0.001 STAT5 *d*-PA 48 h vs. C 48 h and *n*-PA 48 h). IL-3--stimulated ECs were used as positive control (+). *B*: q-RT-PCR analysis of PPARγ mRNA expression in EPCs treated for 24 and 48 h as indicated; data, normalized to the corresponding GADPH mRNA and expressed as mean + SD, are reported as fold induction relative to control values arbitrarily set as 100 (*n* = 9; \**P* \< 0.05, *d*-PA 24 h vs. C 24 h and *n*-PA 24 h; †*P* \< 0.05, *d*-PA 48 h vs. C 48 h and *n*-PA 48 h). *C*: q-RT-PCR analysis of STAT5A mRNA expression in EPCs treated for 24 and 48 h as indicated; data, normalized to the corresponding glyceraldehyde-3-phosphate dehydrogenase mRNA and expressed as mean + SD, are reported as fold induction relative to control values arbitrarily set as 100 (*n* = 9; \**P* \< 0.05, *d*-PA 24 h vs. C 24 h and *n*-PA 24 h; †*P* \< 0.05, *d*-PA 48 h vs. C 48 h and *n*-PA 48 h). *D*: q-RT-PCR analysis of STAT5B mRNA expression in EPCs treated for 24 and 48 h as indicated; data, normalized to the corresponding GADPH mRNA and expressed as mean + SD, are reported as fold induction relative to control values arbitrarily set as 100 (*n* = 9). *E*: Representative ChIP analysis of PPARγ binding to PPRE in A3 and Inter2 sequences of the STAT5A human gene in EPCs treated for 48 h as indicated; densitometric analysis data, normalized to the corresponding Input values and expressed as mean + SD, are reported as relative amount of PCR products (*n* = 9; \**P* \< 0.05, PPARγ on A3 sequence *n*-PA and *d*-PA vs. C; ††*P* \< 0.01, PPARγ on Inter2 sequence *d*-PA vs. C and *n*-PA). *F*: Electrophoretic mobility shift assay of PPARγ binding specificity to the Inter2 sequence of STAT5A gene promoter in 48 h--treated EPCs with *d*-PA. *G*: Firefly luciferase activity and schematic representation of the different human STAT5A pGL3 gene reporter plasmids transfected in EPCs. EPCs were treated for 48 h as indicated; luminescence data, normalized to the corresponding Renilla luciferase values and expressed in arbitrary units as mean + SD, are reported as relative luciferase activity (*n* = 9; \**P* \< 0.05, pGL3-Inter2 and pGL3-Inter2-A3 *d*-PA--treated cells vs. C and *n*-PA--treated cells and also vs. pGL3-Inter2\[mutated\]-A3 *d*-PA--treated cells).](1245fig3){#F3}

Depending on the requested biological response, STAT5--PPARγ complex binds to cyclin D1 or p21^Waf^ gene promoter. {#s23}
------------------------------------------------------------------------------------------------------------------

To evaluate whether STAT5 formed a complex with PPARγ ([@B22]), co-IP experiments were performed. As shown in [Fig. 4*A--C*](#F4){ref-type="fig"}, a STAT5/PPARγ complex containing the activated STAT5A could be detected in *n*-PA-- and *d*-PA--treated cells, suggesting that, although at low level of expression, STAT5A ([Fig. 4*A*](#F4){ref-type="fig"}) binds to PPARγ.

![The STAT5/PPARγ transcriptional complex binds to cyclin D1 or p21^Waf^ promoter depending on the requested biological response. *A*: Representative pSTAT5 and immunoprecipitated (IP) STAT5A expression in EPCs treated for 48 h as indicated; densitometric data, normalized to the corresponding β-actin values and expressed as mean + SD, are reported as relative amount expressed in arbitrary units (*n* = 9; \**P* \< 0.05, pSTAT5: *d*-PA vs. C \[control\] and *n*-PA; †*P* \< 0.05, STAT5A: *d*-PA vs. C and *n*-PA). *B*: Representative co-IP of PPARγ and STAT5A from nuclear extracts of EPCs treated for 48 h as indicated; densitometric data, normalized to the corresponding lamin B1 values and expressed as mean + SD, are reported as relative amount expressed in arbitrary units (*n* = 9; \**P* \< 0.05, PPARγ: *d*-PA vs. C and *n*-PA). *C*: Representative co-IP of pSTAT5/STAT5A and PPARγ from nuclear extracts of EPCs treated for 48 h as indicated; densitometric data, normalized to the corresponding lamin B1 values and expressed as mean + SD, are reported as relative amount expressed in arbitrary units (*n* = 9; \**P* \< 0.05, pSTAT5: *d*-PA vs. C and *n*-PA; †*P* \< 0.05, STAT5A: *d*-PA vs. C and *n*-PA). *D*: Representative co-IP of p21^Waf^ and PCNA from nuclear extracts of EPCs treated for 48 h as indicated; densitometric data, normalized to the corresponding lamin B1 values and expressed as mean + SD, are reported as relative amount expressed in arbitrary units (*n* = 9; \**P* \< 0.05, p21^Waf^: *d*-PA vs. C and *n*-PA; †*P* \< 0.05, PCNA: *d*-PA vs. C and *n*-PA). IL-3--stimulated ECs were used as positive control in *A*--*D* (+, *A*--*C*; C+, *D*). *E*: Representative ChIP analysis of PPARγ and STAT5A binding to cyclin D1 and p21^Waf^ promoters in EPCs treated as indicated at 15 days; densitometric data, normalized to the corresponding Input values and expressed as mean + SD, are reported as relative amount of PCR products (*n* = 9; \**P* \< 0.05, STAT5A on cyclin D1 promoter: *d*-PA vs. C and *n*-PA; †*P* \< 0.05, STAT5A on p21^Waf^ promoter: *d*-PA vs. C and *n*-PA; ‡‡*P* \< 0.01, PPARγ on cyclin D1 promoter: *d*-PA vs. C and *n*-PA; §*P* \< 0.05, PPARγ on p21^Waf^ promoter: *d*-PA vs. C and *n*-PA).](1245fig4){#F4}

Both p21^Waf^ and cyclin D1 promoter regions contain putative response elements for STAT5 and PPARγ ([@B22]). Thus, we inquired whether a *d*-PA and *n*-PA--elicited biological response dictates gene targeting. ChIP assay performed on the promoter region of cyclin D1 ([@B22]) and on that of p21^Waf^ ([Fig. 4*E*](#F4){ref-type="fig"}) clearly demonstrate that indeed the STAT5/PPARγ complex binds to cyclin D1 or p21^Waf^ promoter depending on the stimulus: it binds to cyclin D1 promoter upon *n*-PA, which does not inhibit EPC cell-cycle progression; conversely, it binds to p21^Waf^ promoter upon *d*-PA that induces EPC cell-cycle arrest. A p21^Waf^/PCNA molecular complex preventing PCNA functional activation has been shown to contribute to cell-cycle arrest ([@B40]). Likewise we demonstrated that, in response to *d*-PA only, p21^Waf^ physically interacts with PCNA ([Fig. 4*D*](#F4){ref-type="fig"}).

The relative amount of activated STAT5 regulates EPC progression into the cell cycle. {#s24}
-------------------------------------------------------------------------------------

To evaluate whether STAT5 cell content, and in particular its activated form, represents a crucial determinant of EPC fate, EPCs were transiently transfected with STAT1\*6 ([@B31]) or with the empty vector pCNeo. As shown in [Fig. 5*A*](#F5){ref-type="fig"}, when phosphorylated STAT5 (pSTAT5) content increased, it led to cyclin D1 expression and EPC proliferation ([Fig. 5*B--D*](#F5){ref-type="fig"}) even in the presence of *d*-PA. Consistently, ChIP analysis demonstrated that the increased level of activated STAT5 led the STAT5/PPARγ transcriptional complex to move from the p21^Waf^ gene promoter to that of cyclin D1 ([Fig. 5*E*](#F5){ref-type="fig"}).

![The amount of activated STAT5 regulates EPC progression into the cell cycle. *A*: Representative WB and densitometric analysis of pSTAT5 protein content in EPCs transfected with different STAT1\*6 plasmid concentrations or with the empty vector pCNeo and treated for 48 h with *d*-PA; densitometric data, normalized to the corresponding β-actin values and expressed as mean + SD, are reported as relative amount expressed in arbitrary units (*n* = 9; \*\**P* \< 0.01, STAT1\*6 10 μg vs. pCNeo, STAT1\*6 0.5, 1, and 5 μg). IL-3--stimulated ECs were used as positive control (+). *B*: Proliferation of EPCs transfected with different STAT1\*6 plasmid concentrations or with the empty vector pCNeo and treated for 48 h with *n*-PA or *d*-PA; data are expressed as mean + SD (*n* = 9; \*\**P* \< 0.01, STAT1\*6 10 μg *d*-PA--treated cells vs. pCNeo, STAT1\*6 0.5, 1, 5, and 10 μg *n*-PA--treated cells and also vs. STAT1\*6 0.5, 1, and 5 μg *d*-PA--treated cells). *C*: q-RT-PCR analysis of cyclin D1 and p21^Waf^ mRNA expression in EPCs transfected with different STAT1\*6 plasmid concentration or with the empty vector pCNeo and treated for 48 h with *d*-PA; data, normalized to the corresponding GADPH mRNA and expressed as mean + SD, are reported as *m*-RNA relative amount expressed in arbitrary units (*n* = 9; \**P* \< 0.05, cyclin D1: STAT1\*6 10 μg *d*-PA--treated cells vs. pCNeo, STAT1\*6 0.5, 1, and 5 μg *d*-PA--treated cells; †*P* \< 0.05, p21^Waf^ STAT1\*6 10 μg *d*-PA--treated cells vs. pCNeo, STAT1\*6 0.5, 1, and 5 μg *d*-PA--treated cells). *D*: Representative WB and densitometric analysis of cyclin D1 and p21^Waf^ protein content in EPCs treated for 48 h as indicated; densitometric data, normalized to the corresponding β-actin values and expressed as mean + SD, are reported as relative protein amount expressed in arbitrary units (*n* = 9; \*\**P* \< 0.01, cyclin D1: STAT1\*6 10 μg *d*-PA--treated cells vs. pCNeo, STAT1\*6 0.5, 1, and 5 μg *d*-PA--treated cells; †*P* \< 0.05, p21^Waf^ STAT1\*6 10 μg *d*-PA--treated cells vs. pCNeo, STAT1\*6 0.5, 1, and 5 μg *d*-PA--treated cells). IL-3-- and AGE-stimulated ECs were used as positive controls (+) for cyclin D1 or p21^Waf^, respectively. *E*: Representative ChIP analysis of PPARγ and STAT5A binding to cyclin D1 and p21^Waf^ promoters in EPCs transfected with pCNeo or STAT1\*6 vector and treated for 48 h with *d*-PA; densitometric data, normalized to the corresponding Input values and expressed as mean + SD, are reported as relative amount of PCR products (*n* = 9; \*\**P* \< 0.01, STAT5A on cyclin D1 promoter STAT1\*6 vs. pCNeo; ††*P* \< 0.01, STAT5A on p21^Waf^ promoter STAT1\*6 vs. pCNeo; ‡*P* \< 0.05 PPARγ on cyclin D1 promoter STAT1\*6 vs. pCNeo; §§*P* \< 0.01 PPARγ on p21^Waf^ promoter STAT1\*6 vs. pCNeo).](1245fig5){#F5}

We have previously demonstrated that cultured diabetic EPCs are unable to undergo cell proliferation ([@B25],[@B28]). To assess the biological relevance of the above results, PPARγ, STAT5, and pSTAT5 levels in EPCs isolated from diabetic patients at diagnosis (*d*-EPCs), from longstanding diabetic patients (LS-dEPCs), showing similar NEFA plasma levels, and from healthy blood donors (hEPCs) were analyzed. The results reported in [Fig. 6*A--D*](#F6){ref-type="fig"} demonstrated that, compared with h-EPCs, *d*-EPCs and LS-dEPCs expressed high PPARγ levels, low STAT5A levels, and a barely detectable level of pSTAT5. To further validate these data, the expression of cyclin D1 and p21^Waf^ was evaluated. The results in [Fig. 6*E--H*](#F6){ref-type="fig"} demonstrated that *d*-EPCs and LS-dEPCs, as *d*-PA--treated cells, expressed high levels of p21^Waf^ and low levels of cyclin D1. ChIP assay further confirmed these results, as in hEPCs, STAT5A and PPARγ were both present on the putative response element of cyclin D1 gene promoter, whereas in *d*-EPCs and LS-dEPCs, both proteins were on the p21^Waf^ gene promoter response element ([Fig. 6*I*](#F6){ref-type="fig"}). When parallel experiments were performed by adding 10 mmol/L glucose to *d*-PA, we found that the decrease in STAT5A and of p21^Waf^ expression correlated with STAT5/PPARγ binding to the p21^Waf^ gene promoter and to EPC proliferation and migration ([Supplementary Fig. 7](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0646/-/DC1)). Pioglitazone improves EPC function in type 2 diabetic patients ([@B15]). Consistently, we found that it was able to restore *d*-EPC migration and reduce the percentage of senescent cells, effects not related to STAT5A and PPARγ content ([Supplementary Fig. 8](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0646/-/DC1)).

![The STAT5/PPARγ transcriptional complex binds to p21^Waf^ promoter in *d*-EPCs and LS-dEPCs. *A*: q-RT-PCR analysis of PPARγ mRNA expression in hEPCs, dEPCs, and LS-dEPCs (15 days of cultures); data normalized to the corresponding GADPH mRNA and depicted in box plot are reported as relative mRNA expression in arbitrary units (*n* = 14; \*\**P* \< 0.01, dEPCs and LS-dEPCs vs. hEPCs). *B*: q-RT-PCR analysis of STAT5A mRNA expression in hEPCs, dEPCs and LS-dEPCs (15 days of culture); data normalized to the corresponding GADPH mRNA and depicted in box plot are reported as relative mRNA expression in arbitrary units (*n* = 14; \**P* \< 0.05, dEPCs and LS-dEPCs vs. hEPCs). *C*: Representative WB and densitometric analysis of PPARγ protein content in hEPCs, dEPCs, and LS-dEPCs. Densitometric data, normalized to the corresponding β-actin values and expressed as mean + SD, are reported as relative amount expressed in arbitrary units (*n* = 14; \**P* \< 0.05, dEPCs and LS-dEPCs vs. hEPCs). *D*: Representative WB and densitometric analysis of pSTAT5 and STAT5A protein content in hEPCs, dEPCs, and LS-dEPCs. Densitometric data, normalized to the corresponding β-actin values and expressed as mean + SD, are reported as relative amount expressed in arbitrary units (*n* = 14; \*\**P* \< 0.01, pSTAT5 dEPCs and LS-dEPCs vs. hEPCs; †*P* \< 0.05, STAT5 dEPCs and LS-dEPCs vs. hEPCs). *E*: q-RT-PCR analysis of cyclin D1 mRNA expression in hEPCs, dEPCs, and LS-dEPCs; data normalized to the corresponding GADPH mRNA and depicted in box plot are reported as relative mRNA expression in arbitrary units (*n* = 14; \**P* \< 0.05, dEPCs and LS-dEPCs vs. hEPCs). *F*: q-RT-PCR analysis of p21^Waf^ mRNA expression in hEPCs, dEPCs, and LS-dEPCs; data, normalized to the corresponding GADPH mRNA and depicted in box plot, are reported as relative mRNA expression in arbitrary units (*n* = 14; \**P* \< 0.05, dEPCs and LS-dEPCs vs. hEPCs). *G*: Representative WB and densitometric analysis of cyclin D1 protein content in hEPCs, dEPCs, and LS-dEPCs. Densitometric data, normalized to the corresponding β-actin values and expressed as mean + SD, are reported as relative amount expressed in arbitrary units (*n* = 14; \**P* \< 0.05, cyclinD1 dEPCs and LS-dEPCs vs. hEPCs). *H*: Representative WB and densitometric analysis of p21^Waf^ protein content in hEPCs, dEPCs, and LS-dEPCs. Densitometric data, normalized to the corresponding β-actin values and expressed as mean + SD, are reported as relative amount expressed in arbitrary units (*n* = 14; ††*P* \< 0.01, p21^Waf^ dEPCs and LS-dEPCs vs. hEPCs). *I*: Representative ChIP analysis of PPARγ and STAT5A binding to cyclin D1 and p21^Waf^ promoters in hEPCs, dEPCs, and LS-dEPCs; densitometric data, normalized to the corresponding Input values and expressed as mean + SD, are reported as relative amount of PCR products (*n* = 14; \**P* \< 0.05, STAT5A on cyclin D1 promoter dEPCs and LS-dEPCs vs. hEPCs; ††*P* \< 0.01, STAT5A on p21^Waf^ promoter dEPCs and LS-dEPCs vs. hEPCs; ‡*P* \< 0.05, PPARγ on cyclin D1 promoter dEPCs and LS-dEPCs vs. hEPCs; §§*P* \< 0.01, PPARγ on p21^Waf^ promoter dEPCs and LS-dEPCs vs. hEPCs).](1245fig6){#F6}

*d*-PA effects on BM-CD117^+^ cells and EPC vasculogenic capability. {#s25}
--------------------------------------------------------------------

Different PPARγ agonists inhibit CD34^+^ colony formation, an effect reverted by GW9662, a specific PPARγ inhibitor ([@B23]). To investigate whether *d*-PA also affects BM-derived hematopoietic cell colony formation, BM-CD117^+^ cells were used. Data in [Fig. 7*A*](#F7){ref-type="fig"} show that CD117^+^ clonogenic activity was inhibited by *d*-PA treatment, and GW9662 rescued this effect. These data were further supported by cyclin D1 and p21^Waf^ expression ([Fig. 7*C*](#F7){ref-type="fig"}). Moreover, consistent with data obtained in hEPCs, we found that STAT5A expression was reduced only in response to *d*-PA ([Fig. 7*B*](#F7){ref-type="fig"}). Thus, ChIP assay was performed, and the results reported in [Fig. 7*D*](#F7){ref-type="fig"} demonstrate that *d*-PA, unlike *n*-PA, induces the formation of a STAT5/PPARγ transcriptional complex that specifically binds to p21^Waf^ promoter.

![Effects of *d*-PA on hematopoietic progenitor cells and on EPC vasculogenic capability. *A*: Number of colonies formed by CD117/c-kit^+^ cells treated for 15 days as indicated. In selected experiments, GW9662, a specific PPARγ inhibitor, was added; data are expressed as mean ± SD (*n* = 6; \**P* \< 0.05, *n*-PA and *d*-PA + GW9662 vs. C \[control\]; \*\**P* \< 0.01 *d*-PA vs. C, *n*-PA, and *d*-PA + GW9662). *B*: Representative WB and densitometric analysis of PPARγ, STAT5, and pSTAT5 protein content in cells treated as above indicated; densitometric data, normalized to the corresponding β-actin values and expressed as mean + SD, are reported as fold induction relative to control values arbitrary set as 100 (*n* = 9; \**P* \< 0.05, STAT5A *n*-PA vs. C; \*\**P* \< 0.01, STAT5A *d*-PA vs. C; †*P* \< 0.05, pSTAT5 *n*-PA vs. C; ††*P* \< 0.01, pSTAT5 *d*-PA vs. C; ‡‡*P* \< 0.01, PPARγ *d*-PA vs. C and *n*-PA). IL-3--stimulated ECs were used as positive control (+). *C*: Representative WB and densitometric analysis of cyclin D1 and p21^Waf^ protein content in cells treated for 15 days as indicated; densitometric data, normalized to the corresponding β-actin values and expressed as mean + SD, are reported as fold induction relative to control values arbitrary set as 100 (*n* = 9; \**P* \< 0.05, cyclin D1: *n*-PA vs. C; \*\**P* \< 0.01, cyclin D1: *d*-PA vs. C; ††*P* \< 0.01, p21^Waf^: *d*-PA vs. C and *n*-PA). IL-3-- and AGE-stimulated ECs were used as positive controls (+) for cyclin D1 or p21^Waf^, respectively. *D*: Representative ChIP analysis of PPARγ and STAT5A binding to cyclin D1 and p21^Waf^ promoters in cells treated for 15 days as indicated; densitometric data, normalized to the corresponding Input values and expressed as mean + SD, are reported as relative amount of PCR products (*n* = 6; \*\**P* \< 0.01, STAT5A on cyclin D1 promoter *d*-PA vs. C and *n*-PA; ††*P* \< 0.01, PPARγ on cyclin D1 promoter *d*-PA vs. C and *n*-PA; ‡‡*P* \< 0.01, PPARγ on p21^Waf^ promoter *d*-PA vs. C and *n*-PA). *E*: Tube-like structure formation assay in basement Matrigel matrix of EPCs treated as indicated. Data are expressed as mean + SD (*n* = 3; \**d*-PA vs. C and GW9662 + *d*-PA). *F*: In vivo vasculogenic capability of EPCs treated as indicated. Data are expressed as mean + SD (*n* = 3; \**d*-PA vs. C and GW9662 + *d*-PA). Prelabeled \[fluorescent dye 5- (and 6-)carboxyfluorescein diacetate succinimidyl ester\] human EPCs were used. Anti-fluorescein/Oregon Green polyclonal antibody and horseradish peroxidase--labeled anti-rabbit antibody were used to selectively detect injected cells (brown-stained cells in the image).](1245fig7){#F7}

The role of PPARγ in mediating EPC dysfunction was also investigated by evaluating EPC vasculogenetic capability ([@B28]). Indeed, in vitro and in vivo data demonstrated that *d*-PA--mediated inhibition of EPC vasculogenetic potential could be rescued when the specific PPARγ inhibitor GW9662 was exploited ([Fig. 7*E* and*F*](#F7){ref-type="fig"}).

DISCUSSION {#s26}
==========

NEFAs and in particular PA and OA are biomarkers of poor metabolic control in diabetic patients ([@B1],[@B2]). Among NEFA, PA is a well-known, natural, low-affinity PPAR ligand ([@B41]). PPARs belong to the nuclear receptor transcription factor family ([@B8],[@B12]). Different PPAR isoforms have been characterized owing to their tissue specificity ([@B8],[@B12]), and two diverse variants of PPARγ ([@B1],[@B2]) have been described ([@B42]). Unlike PPARγ2, PPARγ1 seems to modulate pivotal biological functions in the cardiovascular system ([@B43]). Studies to dissect the effects PPARγ agonists, such as pioglitazone, on vascular cells are still debated ([@B15],[@B44],[@B45]). We have previously shown that, unlike agonist-independent PPARγ expression, agonist-dependent PPARγ expression inhibits EPC cell-cycle progression ([@B22]), suggesting that PPARγ transcriptional activity is much more complex than expected.

PPARγ transcriptional activity mainly depends on the formation of heterodimers with the nuclear retinoid X receptor-α ([@B8]). However, we have previously shown that, in IL-3--mediated EPC expansion, PPARγ formed heterodimers with the activated STAT5A to induce cyclin D1 gene transcription ([@B22]). STAT5A, in this particular context, transcriptionally controls PPARγ expression ([@B22]). In diabetes, multiple factors, such as hyperglycemia, oxidative stress, and advanced glycosylation end products (AGEs), have been investigated as potential mediators of EPC dysfunction ([@B46]). Conversely, only few data are so far available on the effects exerted by elevated plasma NEFA concentrations on EPC biology ([@B19],[@B20],[@B47]). We report in this study that, consistent with the low ligand affinity of PA for PPARγ, only *d*-PA was able to induce PPARγ expression in EPCs. Moreover, we demonstrated that as the result of its expression/activation, EPCs undergo p21^Waf^-mediated cell-cycle arrest. Moreover, as previously shown ([@B22]), we found that *d*-PA--mediated inhibition of EPC progression into the cell cycle is associated with a reduced STAT5A expression. Evidence has been provided that EPC mobilization is impaired in a diabetic setting ([@B28]). We demonstrate that *d*-PA prevented stromal cell--derived factor 1α (SDF-1α)--mediated EPC migration as well, suggesting that *d*-PA might also impair EPC--BM mobilization, a crucial event for EPC-mediated vascular protection. A reciprocal transcriptional cross-talk between STAT5 and PPARγ has been described in different tissue ([@B48],[@B49]). Three different regulatory regions have been identified in the human STAT5 gene promoter ([@B39]). Regions I and II were recognized as putative STAT5A and STAT5B promoters, respectively, whereas region III has been described as a negative regulatory element shared by both genes. Region I and III contain different sequences denoted as A1, A2, and A3 (region I) and Inter1 and Inter2 (region III) ([@B39]). By interrogating NHRScan, two different PPREs were found in A3 and Inter2, further confirming that PPARγ can positively or negatively modulate STAT5A expression. Consistent with the low STAT5A content observed in response to *d*-PA, we first demonstrated that PPARγ binds to Inter2 to negatively regulate STAT5A expression. Moreover, we failed to detect changes in STAT5B expression, indicating that PPARγ binds to Inter2 to specifically regulate STAT5A expression.

Closed putative response elements for STAT5 and PPARγ are present in the promoter region of both p21^Waf^ and cyclin D1 genes ([@B22]). We demonstrated that in *d*-PA--treated EPCs, both STAT5A and PPARγ bind to p21^Waf^ promoter, indicating that although at low level of expression, STAT5A can form a transcriptional complex with PPARγ to induce the expression of p21^Waf^. However, as the STAT5/PPARγ complex was also detected in *n*-PA--treated EPCs, we hypothesized that depending on the relative amount of STAT5A, the same transcriptional complex can target discrete genes. In fact, in agreement with the biological effect associated with *n*-PA treatment, we found that the STAT5/PPARγ complex stably binds to cyclin D1 gene promoter. p21^Waf^ modulates cell-cycle progression by forming a complex with cyclins, cyclin-dependent protein kinases, and PCNA ([@B40]). It is known ([@B40]) that in absence of cyclins and cyclin-dependent protein kinases, p21^Waf^ blocks progression into the cell cycle by physically interacting with PCNA, thus resulting in inhibition of PCNA-dependent activation of DNA polymerase δ. Our finding that p21^Waf^--PCNA interaction could be only detected in *d*-PA--challenged EPCs indicates that such a mechanism might be crucial for regulating cell-cycle progression in our experimental conditions as well.

The role of STAT5 in controlling hematopoietic cell ([@B23]), EPC, and vascular cell ([@B29]) progression into the cell cycle has been extensively documented. A large body of evidence indicates that STAT5 regulates discrete biological functions by forming homodimeric (STAT5A/STAT5A or STAT5B/STAT5B) or heterodimeric (STAT5A/STAT5B, STAT5A/PPARγ, and STAT5/estrogen receptor) transcriptional complexes ([@B22],[@B50]). However, whether and how the relative amount of individual transcriptional factor can modulate gene targeting and cell fate has not been investigated so far. In this study, we show that STAT5A content actually drives gene targeting and ultimately EPC fate. Deregulation of early hematopoiesis driven by PPARγ-mediated downregulation of STAT5 has been described ([@B23]). In this study, we provide a proof of concept that, by regulating the relative amount of STAT5, *d*-PA controls gene targeting and BM-CD117^+^ cell proliferation as well. The biological relevance of these results is supported by the findings that inhibition of *d*-PA--induced PPARγ activity rescued BM-CD117^+^ cell colony formation. Moreover, as in mature ECs *d*-PA did not regulate STAT5 expression and cell-cycle progression, it is conceivable to assume that such a mechanism is relevant for immature cells only. This would be particularly relevant in specific clinical settings wherever re-entry into the cell cycle, to promote progenitor cell expansion, is needed.

EPCs contribute to maintain endothelial integrity, a crucial event to prevent vascular complications in diabetes ([@B13],[@B46]). Evidence has been provided that hyperglycemia and its related metabolic disorders impair EPC bioavailability in a diabetic setting ([@B13],[@B46]). In this study, we demonstrated how mechanistically *d*-PA and possibly a high level of NEFA plasma concentration in diabetic patients might contribute to EPC dysfunction ([@B19],[@B20],[@B47]). This possibility is also sustained by data obtained in EPCs subjected to high glucose and *d*-PA. Additional support to the role of *d*-PA--driven PPARγ transcriptional activity and EPC dysfunction is provided by the observation that by interfering with PPARγ activity, EPC vasculogenetic properties could be rescued. Plasma metabolomic profiling identifies as type 2 diabetes biomarkers PA, OA, and SA ([@B2],[@B3]). We did not measure PA, OA, and SA plasma concentrations in diabetic patients. However, PA represents ∼30% of total plasma NEFAs ([@B6]). This observation, together with the finding that when OA or SA diabetic concentrations were exploited in vitro we failed to detect significant effects on EPCs' functional capabilities, suggest that NEFA-mediated EPC toxic effect might depend on *d*-PA.

Pioglitazone treatment has been shown to improve the imbalance between endothelial damage and repair in a diabetic setting ([@B15],[@B44],[@B45]). However, whether this effect is direct or the result of its anti-inflammation and/or lipid modification is still debated ([@B15]). Our data demonstrated that pioglitazone protected *d*-EPCs from senescence and rescued their functional capability. However, this effect was not associated with changes in STAT5A and PPARγ content. This suggests that in vivo, the mechanisms involved in pioglitazone-mediated improvement of EPC bioavailability are much more complex than expected and require additional investigations.

Clinical data in nondiabetic patients sustain that favorable metabolic effect and cardiovascular protection are associated with mono- and polyunsaturated fatty acid administration ([@B7]). We found that physiological concentration of OA was able to rescue *d*-PA--induced EPC cell-cycle arrest. However, as OA plasma concentrations are increased in type 2 diabetes and contribute to the global increase of NEFAs ([@B4],[@B5]), a potential deleterious effect of OA administration in diabetic patients has to be taken into consideration. As a proof of concept, metabolomic included OA among type 2 diabetes lipid biomarkers ([@B3],[@B5]). Consistently, when *d*-OA concentrations were used in combination with *d*-PA, we failed to detect any protection, thus indicating that dietary interventions in diabetic patients should be targeted to normalize NEFA concentrations rather than merely suggest OA supplementation.

In conclusion, these data first demonstrate how mechanistically *d*-PA can contribute to EPC and BM-derived hematopoietic dysfunction and provide the rationale to exploit such a target for novel therapeutic strategies.
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